A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine ...

ICMR and Panacea Biotec conduct third phase trials for indigenous dengue vaccine in India with promising results.

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...

The one-shot vaccine, developed by Panacea Biotec and branded as DengiAll, is being tested through a multi-centre, ...

An ongoing Phase III clinical trial of DengiAll, a one-shot dengue vaccine developed by Panacea Biotec, is progressing in ...

The report, which covered the week of June 16-22, revealed that 781 confirmed cases were reported out of 5,943 suspected cases across 20 states and 101 LGAs ...

Donald Trump again has threatened a tariff on imported drugs, but has given the drug makers a year or so "to get their act ...

With COVID-19 continuing to mutate and over 40 million immunocompromised Americans still at risk, GeoVax’s GEO-CM04S1 vaccine offers potential broader, more durable protection through a unique ...

Here, we review the most recent findings on the Crimean–Congo hemorrhagic fever virus molecular biology and pathogenesis, including aspects of virus–host cell interactions.